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mean liver volume remained stable at 0.9 MN (non-significant,
n=63). In splenectomized-switch patients, mean hemoglobin
remained stable: 13.5 to 13.4 g/dL (non-significant, n=36) mean
platelet count increased from 295 to 319 x109/L (p=0.05, n=34)
mean liver volume remained stable: 0.9 to 1 MN (non-significant,
n=15). Mean chitotriosidase levels decreased in all groups, with
significant reductions in treatment-naïve patients (1325 to 308
nmol/mL/hr, p=0.03, n=6) and non-splenectomized-switch patients
(838 to 725 nmol/mL/hr p=0.02, n=86). These real-world results
are consistent with those reported in eliglustat clinical trials.
doi:10.1016/j.ymgme.2018.12.252
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Generation of iPS cells derived from skin fibroblasts of patients
with Fabry disease using RNA-reprogramming
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Chen Wua, Takeo Iwamotob, Yoshikatsu Etoa, aAdvanced Clinical
Research Center, Kawasaki, Japan, bTokyo Jikei University School of
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Fabry disease is a lysosomal metabolic disorder with X-linked
inheritance caused by a deficiency of alpha-galactosidase which leads
to accumulation of globotriaosylceramide (Gb3) in various organs.
Clinical features of Fabry disease are renal, cardiac and CNS involve-
ment. However, precise cellular pathogenesis in Fabry disease is still
unknown. The iPS technology may be useful for the understanding of
pathogenetic mechanism of lysosomal storage disease including Fabry
disease. The generation of iPS cells generally have been carried out by
the use of Sendai virus vector or episomal vector, but these
technologies need the environmental attention and equipment for
handling viruses. Therefore, we focused on RNA-reprogramming
procedure. Skin fibroblasts from control and Fabry disease were
transfected with reprogramming factors (Oct4, Sox2, Klf4, cMyc,
Nanog, Lin28), interferon factors (B18, E3, K3), RNA and microRNA
and formed iPS colonies were obtained after several cell passages and
surveyed for morphological and biochemical studies. Using this
method, no virus is used and feeder cells are not required, and also
iPS cells can be efficiently obtained in a short period of time. Using this
method, the iPS cells were successfully established from healthy
human skin fibroblasts and skin fibroblasts derived from three Fabry
male sibling patients in same family. Expression of surface markers
and undifferentiated markers in these iPS cells showed positive,
demonstrated by immunostaining and RT-PCR. Generated iPS cells
from these Fabry patients were confirmed as iPS cells by various
pluripotency markers. Our RNA reprograming procedure to generate
iPS cells could be more widely used for understanding of pathogenetic
mechanism of various lysosomal diseases including Fabry disease.
doi:10.1016/j.ymgme.2018.12.253
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Unexpected genetic findings in a Gaucher disease patient analysed
by NGS-based panel sequencing
Marta Moradoa, Gloria Muñozb, Miguel Pirisb, Alejandro Sanzb, Jesus
Villarrubiab, Francisco J. del Castillob, aHospital Universitario La Paz,
Madrid, Spain, bHospital Universitario Ramón y Cajal, IRYCIS, Madrid,
Spain
A 40-year-old man with a history of mild idiopathic or immune
thrombocytopenia since childhood was referred for consultation due
to splenomegalia. He had mild normocytic anemia and thrombocy-
topenia, a markedly enlarged spleen (22 cm) with several focal
lesions without lymphadenopathy, and typical Gaucher cells were
observed in bone marrow smears. Analysis of genomic DNA by
means of the Next-Generation Sequencing (NGS)-based Sple-
nomegalia and Thrombocytopenia resequencing gene panel (STP
version 1, 74 genes) and segregation analyses indicated that the
patient was compound heterozygous for the known pathogenic
mutations p.(Asn409Ser) (formerly N370S) and p.Leu483Pro (for-
merly L444P) at the GBA gene. Determination of beta-glucosidase
activity indicated that only residual levels were present, confirming a
diagnostic of Gaucher disease. However, further analysis of panel
data revealed that the patient was also hemizygous for a pathogenic
mutation, p.(Arg24*), at the G6PD gene on chromosome X. Quanti-
fication of glucose-6-phosphate dehydrogenase in blood confirmed
reduced activity, well below normal levels. We did not find any
evidence of previous episodes of acute anemia, even after exposure
to quinine or Vicia faba. Our results indicate that, by simultaneously
interrogating many genes involved in lysosomal storage diseases
(LSDs) and their differential diagnoses, NGS panel sequencing helps
identifying additional mutations that may modulate the phenotypic
presentation and therefore suggest different therapeutic approaches.
Funding: This work was supported by Sanofi Genzyme.
doi:10.1016/j.ymgme.2018.12.254
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Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR) were found as an immune adaptive mechanism in bacteria
and quickly were applied to various fields as a promising tool for gene
editing. Lysosomal storage diseases (LSDs) are a group of metabolic
disorders caused by defects in lysosomal proteins leading to accumu-
lation of undigestedmacromoleculeswithin the cells. The lack of good
in vitro models hinders research of the pathophysiologic mechanisms
and the development of new therapies. Induced pluripotent stem cells
(iPSCs) are patient-specific and can be differentiated in any cell type.
The advantage of iPSCs is to enable targeted studies in cells with the
patient’s own background leading to more straightforward results
than other models. Combining CRISPR and iPSCs is, therefore, a
promising strategy. We aim to use CRISPR/Cas-mediated gene editing
to provide more specific cellular models of disease, to correct causal
mutations in LSDs and to create mutants for functional studies. In this
work, we generated and characterized iPSCs from human fibroblasts
obtained from Gaucher and Fabry patients (through Gaslini Institute)
and will edit them with a CRISP/Cas9 approach. Because both gene
editing and iPSCs generation require manipulating the cell’s genome,
we envisagemultiple check points along theworkflow. It will be useful
to compare the “native” mutated cells with the corrected cells that
modulate the “disease in a dish”. Gene editing is still recent and the
methods require improvement, namely increasing transfection rates
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andmutagenesis efficiencywith less off-targets. Nevertheless, CRISPR/
Cas is a promising alternative to other therapies, and every result
contributes to the enhancement of this technology, broadening the
validation of CRISPR application and making it an accessible option.
doi:10.1016/j.ymgme.2018.12.255
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Are we missing complex rearrangements by next generation
diagnostic approaches: A case report of a complex rearrangement
in MPS II
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Mucopolysaccharidosis type II (MPS II) is caused by deficiency of
Iduronate-2-sulfatase (IDS) that leads to accumulation of undegraded
glycosaminoglycans. So far, over 630mutations have been described for
the IDS gene in theHumanGenemutationdatabase andonly 2%of these
are classified as complex rearrangements. Here, we present the
molecular diagnosis odyssey of an MPS II patient. Non-consanguineos
parents had 3 children, the first daughter died with 2.6 years with no
confirmed diagnosis but dysmorphic features, the second was a
stillbirth with facial dysmorphic features at birth and the third son
(proband) died with 6.1 years. He started walking with 2 years of age
and had severly impaired speechdevelopment limited to fewwords. He
started developing seizures at 4 years of age. Clinical examination
revealed: short stature, coarse facial features, neurological impairment,
hepatosplenomegaly, proximal muscle weakness, joint rigidity, cardi-
opathy, dysostosis multiplex, macular degeneration, retinopathy, and
hearing loss. The biochemical diagnosis was confirmed at 5.11 years by
fluorimetry in dried blood spot. Next generation sequencing of the IDS
by Illumina platform and MLPA analyses of the IDS gene did not reveal
any clinically significant variant. Sanger sequencing followed by gel
electrophoresis revealed a complex rearrangement within intron 3 and
intron 7 of the IDS gene and the IDS2 pseudogene. This rearrangement
have already been described in the literature. The patient died with 6.1
years of age due to pneumonia. In conclusion, we should be carefull
when using solely next generation sequencing approaches for the
molecular diagnosis of MPS II patients or MLPA taking into consider-
ation the limitations of these methodologies for the identification of
complex rearrangements. The delay in diagnosis of this patient
contributed to his premature death due to the lack of treatment that
could have helped to delay disease progression if started early.
doi:10.1016/j.ymgme.2018.12.256
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Accreditation: A challenge for a research laboratory
Patricia Moreno, Alfredo Uribe, Universidad de los Andes, Bogota,
Colombia
A research laboratory focuses its efforts on the development of
experiments bringing benefit to the entire scientific community. In
fact, current dynamics have led results obtained by several research
groups to be of diagnostic value, particularly for those working with
low frequency diseases. This situation has allowed research labora-
tories to incorporate concepts such as quality, quality assurance,
certification, and accreditation, among other quality-related con-
cepts. Therefore, promotion and implementation of quality manage-
ment systems (QMS) has become as opportune as necessary. The
international quality standards under which a QMS can be imple-
mented are based on ISO standards. One of them is ISO/IEC17025,
which establishes the requirements that must be met by testing and
calibration laboratories. This standard is based on ISO 9000 rules but
incorporates technical requirements essential to achieve accredita-
tion. The ISO/IEC17025 standard is applied with the objective of
demonstrating that testing and calibration laboratories are techni-
cally competent and that their results are accurate. For the
accreditation process (NTC-ISO/IEC17025:2005-standard) our labo-
ratory selected 6 assays of lysosomal enzymatic activity performed in
DBS. This process has been carried out in 2 stages: 1. Implementa-
tion: a.Diagnosis: At initial evaluating laboratory status, it was found
compliance in 20% of the standard b.Planning: Activities were
determine to fill existing gaps c.Design: Strategies to comply with
the requirements of the standard were defined: process map and
100% of documentary support d.Implementation: Disclosure and
application of the policy/objectives/documentary support were
carried out e.Evaluation: An internal audit concluded that the
effectiveness of the implementation was 80%. After solving the
nonconformities, we proceeded to stage 2. Application: The applica-
tion was made to the ONAC. a.Documentary evaluation: ONAC’s
evaluation team declared 95% compliance of documentary support.
b.On-site evaluation: the conclusion was that efficiency of the QMS
accomplished 96%.
doi:10.1016/j.ymgme.2018.12.257
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CRISPR/Cas9 mediated insertion of α-L-iduronidase (IDUA) and
anti-PE receptor in B-lymphocytes for selective activation into
long-lived plasma cells for sustainable IDUA expression
Branden Moriarity, University of Minnesota, Minneapolis, MN, United
States
Mucopolysaccharidosis type I is a rare inherited lysosomal
storage disorder caused by mutations in the IDUA gene. IDUA
deficiency results in the accumulation of glycosaminoglycans
(GAGs), which ranges in clinical severity from Scheie syndrome
(mild form) to Hurler syndrome (Severe form). At present enzyme
replacement therapy (ERT) and bone marrow transplantation (BMT)
are the standard of care for this disease1 . In order to develop new
approaches to treating this disease we exploit the unique character-
istic that B cells differentiate into antibody producing long-lived
plasma cell. We use CRISPR/Cas9 2 mediated homologous directed
repair (HDR) for site-specific insertion to co-express a therapeutic
gene (IDUA) and phycoerythrin (PE). CRISPR/Cas9 system will create
a double strand break at the endogenous B-cell receptor (BCR) of the
B cell genome where homologous directed repair will facilitate the
insertion of a therapeutic cassette under the expression of a
synthetic promoter. A successfully engineered B cell will produce
both IDUA and the PE receptor. A large quantity of IDUA will be
secreted into the extracellular environment and the PE receptor will
be transported to the cell membrane, which will allow us to
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